Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
Subtype terms (4)
More specific conditions that are subtypes of Lymphoma, T-Cell, Cutaneous in the MeSH hierarchy.
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
157 drugs (110 approved, 47 experimental)
- Lymphomatoid Papulosis
7 drugs (6 approved, 1 experimental)
- Mycosis Fungoides
90 drugs (62 approved, 28 experimental)
- Sezary Syndrome
125 drugs (81 approved, 44 experimental)
Drugs by status
Approved for this indication (6)
Phase 4 trials (3)
Phase 3 trials (4)
Phase 2 trials (46)
- afm13
- tazarotene
- atezolizumab
- apo-866
- belinostat
- bnz132-1-40
- busulfan
- lenalidomide
- tofacitinib
- doxycycline
- dimethyl fumarate
- durvalumab
- e7777
- enzastaurin
- gemcitabine
- zanolimumab
- iph4102
- pembrolizumab
- pentostatin
- ritlecitinib
- quisinostat
- resiquimod
- resminostat
- sitagliptin
- sgn-30
- cyclosporine
- cyclophosphamide
- stem cells
- everolimus
- gla-se
- +16 more
Phase 1 trials (26)
Organizations
Organization Involved with Phase 4 Indications (17)
- Eisai
- Bausch Health Companies
- Mallinckrodt
- National Cancer Institute (NCI)
- University of Pittsburgh
- Boston University
- Case Western Reserve University
- Madrilenian Group of Cutaneous Lymphomas
- Polish Lymphoma Research Group
- Tufts University
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- Yale University
- Vanderbilt University
- University of Minnesota
- Rush University
- University of Texas at Houston
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (98)
- 4SC AG
- Galderma
- Actelion
- Celgene
- BioCryst
- Emergent BioSolutions
- Roche
- Eli Lilly
- MedImmune
- Pfizer
- Tibotec
- Angimmune LLC
- BeOne Medicines
- Cyclacel Pharmaceuticals, Inc.
- Innate Pharma
- Karyopharm Therapeutics Inc
- Millennix
- Valerio
- OncoSec Medical Incorporated
- miRagen Therapeutics, Inc.
- Otsuka
- Neumedicines Inc.
- TetraLogic Pharmaceuticals
- The Christie NHS Foundation Trust
- National Institutes of Health (NIH)
- National Cancer Center, Korea
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- Cancer and Leukemia Group B (CALGB)
- University of London
- +68 more
Organization Involved with Phase 1 Indications (30)
- PPD
- Spectrum Pharmaceuticals
- Amgen
- Morphotek
- AstraZeneca
- Arno Therapeutics
- Bio-Path Holdings, Inc.
- Mundipharma
- Rhizen Pharmaceuticals SA
- Sorrento Therapeutics, Inc.
- Therapeutics, Inc.
- Translational Drug Development
- AIDS Malignancy Consortium
- Temple University
- Johns Hopkins University
- Southwest Oncology Group
- University of Michigan
- University of Toronto
- Wayne State University
- University of California, San Francisco
- University of Cologne
- University of Colorado, Denver
- University of North Carolina at Chapel Hill
- Department of Veteran Affairs
- The Leukemia and Lymphoma Society
- Veristat, Inc.
- Peter MacCallum Cancer Centre
- Genzada Pharmaceuticals
- SciTech Development, LLC
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (2)